Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism

Westlind-Johnsson, Anna, Malmebo, Sarah, Johansson, Anna, Otter, Charlotta, Andersson, Tommy B., Johansson, Inger, Edwards, Robert J., Boobis, Alan R. +1 more·2003·Drug Metabolism and Disposition
DOI 10.1124/dmd.31.6.755

Cited by (256)

Items 101–200 of 256

  1. Use of an in vitro–in silico testing strategy to predict inter-species and inter-ethnic human differences in liver toxicity of the pyrrolizidine alkaloids lasiocarpine and riddelliine
    Jia Ning, Lu Chen, Marije Strikwold, Jochem Louisse, Sebastiaan Wesseling, Ivonne M.C.M. Rietjens · 2019 · Archives of Toxicology
  2. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations
    Markus Schirmer, Mohammad Reza Toliat, Michael Haberl, Anita Suk, Landry K. Kamdem, Kathrin Klein, Jürgen Brockmöller, Peter Nürnberg, Ulrich M. Zanger, Leszek Wojnowski · 2006 · Pharmacogenetics and Genomics
  3. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist
    Shin Takusagawa, Kanako Yajima, Aiji Miyashita, Shotaro Uehara, Takafumi Iwatsubo, Takashi Usui · 2012 · Xenobiotica
  4. CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers
    Tsuyoshi Fukuda, S Onishi, Shuichi Fukuen, Yuka Ikenaga, Masako Ohno, K Hoshino, Katsumi Matsumoto, A Maihara, Kouichi Momiyama, T Ito et al. · 2003 · The Pharmacogenomics Journal
  5. CYP3A5 mRNA Degradation by Nonsense-Mediated mRNA Decay
    Florent Busi, Thierry Cresteil · 2005 · Molecular Pharmacology
  6. The X-Ray Crystal Structure of the Human Mono-Oxygenase Cytochrome P450 3A5-Ritonavir Complex Reveals Active Site Differences between P450s 3A4 and 3A5
    Mei‐Hui Hsu, Üzen Savas, Eric F. Johnson · 2017 · Molecular Pharmacology
  7. In vitro inhibitory effect of West African medicinal and food plants on human cytochrome P450 3A subfamily
    Amégnona Agbonon, Kwashie Eklu‐Gadegbeku, Kodjo A. Aklikokou, Messanvi Gbéassor, Koffi Akpagana, Teresa W. Tam, John Thor Arnason, Brian C. Foster · 2010 · Journal of Ethnopharmacology
  8. Expression, Activity and Regulation of CYP3A in Human and Rodent Brain
    Cindy L.A. Woodland, T. T. Huang, Elzbieta A Gryz, Reina Bendayan, J. Paul Fawcett · 2008 · Drug Metabolism Reviews
  9. The missing linkage: what pharmacogenetic associations are left to find inCYP3A?
    Minoli A. Perera · 2009 · Expert Opinion on Drug Metabolism & Toxicology
  10. Foetal and adult human CYP3A isoforms in the bioactivation of organophosphorothionate insecticides
    Franca M. Buratti, Claudia Leoni, Emanuela Testai · 2006 · Toxicology Letters
  11. Regulation of PXR and CAR by protein-protein interaction and signaling crosstalk
    Peter O. Oladimeji, Hongmei Cui, Chen Zhang, Taosheng Chen · 2016 · Expert Opinion on Drug Metabolism & Toxicology
  12. Pharmacogenetics of the Cytochrome P450 Enzyme System: Review of Current Knowledge and Clinical Significance
    Amal Al‐Omari, Daryl J. Murry · 2007 · Journal of Pharmacy Practice
  13. Lessons from the CYP3A4 Promoter
    Erin G. Schuetz · 2004 · Molecular Pharmacology
  14. Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis
    Raj Vuppalanchi, Tiebing Liang, Chirayu Pankaj Goswami, Rohit Nalamasu, Lang Li, David R. Jones, Rongrong Wei, Wanqing Liu, Vishal Sarsani, Sarath Chandra Janga et al. · 2013 · PLoS ONE
  15. Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5
    Matthew G. Soars, Ken Grime, Robert J. Riley · 2006 · Xenobiotica
  16. A SIGNIFICANT DRUG-METABOLIZING ROLE FOR CYP3A5?
    J. Andrew Williams, Jack Cook, Susan I. Hurst · 2003 · Drug Metabolism and Disposition
  17. Hepatic cytochrome P450s play a major role in monocrotaline-induced renal toxicity in mice
    Jun Yao, Chenggang Li, Likun Gong, Chenchen Feng, Chun-zhu Li, Man Gao, Yang Luan, Xinming Qi, Jin Ren · 2013 · Acta Pharmacologica Sinica
  18. A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs
    Laura Molenaar‐Kuijsten, Dorieke E M van Balen, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huitema · 2021 · Frontiers in Pharmacology
  19. Impact of CYP3A5 Genotype on Tacrolimus Versus Midazolam Clearance in Renal Transplant Recipients: New Insights in CYP3A5-Mediated Drug Metabolism
    Hylke de Jonge, Henriëtte de Loor, Kristin Verbeke, Yves F. Ch. Vanrenterghem, Dirk R. J. Kuypers · 2013 · Pharmacogenomics
  20. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer
    Susanna Leskelä, Emiliano Honrado, Cristina Montero‐Conde, Iñigo Landa, Alberto Cascón, Rocío Letón, Paloma Talavera, Jose M. Cozar, A Concha, Mercedes Robledo et al. · 2007 · Endocrine Related Cancer
  21. Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor
    Claudia P. Cortés, Marco Siccardi, Ammara Chaikan, Andrew Owen, Guijun Zhang, Charles J. L. la Porte · 2012 · Therapeutic Drug Monitoring
  22. Identification of Cytochrome P450 Enzymes Involved in the Metabolism of FK228, a Potent Histone Deacetylase Inhibitor, in Human Liver Microsomes
    Toshifumi Shiraga, Zenzaburo Tozuka, Rika Ishimura, Akio Kawamura, Akira Kagayama · 2005 · Biological and Pharmaceutical Bulletin
  23. Pharmacogenetic Determinants of Human Liver Microsomal Alfentanil Metabolism and the Role of Cytochrome P450 3A5
    Theresa Mariero Klees, Pamela R. Sheffels, Kenneth E. Thummel, Evan D. Kharasch · 2005 · Anesthesiology
  24. The Development of a Cocktail CYP2B6, CYP2C8, and CYP3A5 Inhibition Assay and a Preliminary Assessment of Utility in a Drug Discovery Setting
    Charles J. O’Donnell, Ken Grime, Paul F. Courtney, Dean Slee, Robert J. Riley · 2006 · Drug Metabolism and Disposition
  25. Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: Some answers but still questions*1
    Grant R. Wilkinson · 2004 · Clinical Pharmacology & Therapeutics
  26. Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations
    Zoe E. Barter, H. F. Perrett, Karen Rowland Yeo, Delphine Allorge, Martin S Lennard, Amin Rostami‐Hodjegan · 2010 · Biopharmaceutics & Drug Disposition
  27. Metabolism of Beclomethasone Dipropionate by Cytochrome P450 3A Enzymes
    Jessica K. Roberts, Chad D. Moore, Robert M. Ward, Garold S. Yost, Christopher A. Reilly · 2013 · Journal of Pharmacology and Experimental Therapeutics
  28. Identification of polymorphisms in the 3′-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism
    Lauren E. Oleson, Lisa Lvon Moltke, David J. Greenblatt, Michael H. Court · 2010 · Xenobiotica
  29. Polymorphisms of human nuclear receptors that control expression of drug-metabolizing enzymes
    Allan B. Okey, Paul Christopher Boutros, Patricia A. Harper · 2005 · Pharmacogenetics and Genomics
  30. Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction
    Curtis E. Haas, Daniel Alan Brazeau, Denise Cloen, Brent M. Booker, Valerie A. Frerichs, Colleen Zaranek, Reginald F. Frye, Thomas J. Kufel · 2005 · European Journal of Clinical Pharmacology
  31. CYP3A5*3 and CYP3A4*1B Allele Distribution and Genotype Combinations: Differences Between Spaniards and Central Americans
    B. Sinués, Jorge Vicente-Romero, Ana Fanlo, Patricia Vásquez, Juan Carlos Medina, E Mayayo, Blanca Conde, Izaskún Arenaz, Begoña Martínez‐Jarreta · 2007 · Therapeutic Drug Monitoring
  32. Expression of Cytochromes P450 3A and P‐Glycoprotein in Human Large Intestinse in Paired Tumour and Normal Samples
    Roberto Canaparo, Anna Nordmark, Niklas Finnström, Stefan Lundgren, Janeric Seidegård, Bengt W. Jeppsson, Robert Jeffrey Edwards, Alan R. Boobis, Anders Rane · 2006 · Basic & Clinical Pharmacology & Toxicology
  33. The CYP3A4*18 Allele, the Most Frequent Coding Variant in Asian Populations, Does Not Significantly Affect the Midazolam Disposition in Heterozygous Individuals
    Su‐Jun Lee, Sang Seop Lee, Hye‐Eun Jeong, Ji‐Hong Shon, Ji-Young Ryu, Yu Eun Sunwoo, Kwang‐Hyeon Liu, Wonku Kang, Young-Ju Park, Chi-Mann Shin et al. · 2007 · Drug Metabolism and Disposition
  34. Effect of Age on in Vitro Triazolam Biotransformation in Male Human Liver Microsomes
    Kiran C. Patki, Lisa Lvon Moltke, Jerold S. Harmatz, Leah M. Hesse, Michael H. Court, David J. Greenblatt · 2004 · Journal of Pharmacology and Experimental Therapeutics
  35. Regional Distribution of Cytochrome P450 mRNA Expression in the Liver and Small Intestine of Cynomolgus Monkeys
    Yasuharu Nakanishi, Akinori Matsushita, Kiyomi Matsuno, Kazuhide Iwasaki, Masahiro Utoh, Chika Nakamura, Yasuhiro Uno · 2010 · Drug Metabolism and Pharmacokinetics
  36. Pharmacogenetics of Vascular Risk Factors in Alzheimer’s Disease
    Ramón Cacabelos, Arun Meyyazhagan, Juan C. Carril, Pablo Cacabelos, Óscar Teijido · 2018 · Journal of Personalized Medicine
  37. Role of reactive metabolites in the circulation in extrahepatic toxicity
    Roy M. Irving, Adnan A. Elfarra · 2012 · Expert Opinion on Drug Metabolism & Toxicology
  38. Role of Human Pregnane X Receptor in Tamoxifen- and 4-Hydroxytamoxifen-Mediated CYP3A4 Induction in Primary Human Hepatocytes and LS174T Cells
    Rucha S Sane, Donna J. Buckley, Arthur R. Buckley, Srikanth C. Nallani, Pankaj B. Desai · 2008 · Drug Metabolism and Disposition
  39. Introduction to Clinical Pharmacology
    Rommel G. Tirona, Richard B. Kim · 2016 · Elsevier eBooks
  40. CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation
    Yue Dong, Qinxia Xu, Ruidong Li, Yifeng Tao, Quanbao Zhang, Jianhua Li, Zhenyu Ma, Conghuan Shen, Mingkang Zhong, Zhengxin Wang et al. · 2021 · Gene
  41. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments
    Elliot M. Berinstein, Andrew P. Levy · 2017 · Expert Opinion on Drug Metabolism & Toxicology
  42. CYP3A phenotypes and genotypes in North Indians
    Naushad Rais, Yogesh Kumar Chawla, Krishan Kumar Kohli · 2006 · European Journal of Clinical Pharmacology
  43. Marmoset Cytochrome P450 3A4 Ortholog Expressed in Liver and Small-Intestine Tissues Efficiently Metabolizes Midazolam, Alprazolam, Nifedipine, and Testosterone
    Shotaro Uehara, Yasuhiro Uno, Kazuyuki Nakanishi, Sakura Ishii, Takashi Inoue, Erika Sasaki, Hiroshi Yamazaki · 2017 · Drug Metabolism and Disposition
  44. A Novel Polymorphic Cytochrome P450 Formed by Splicing of CYP3A7 and the Pseudogene CYP3AP1
    Cristina Rodríguez‐Antona, Magnus Axelson, Charlotta A. Otter, Anders Rane, Magnus Ingelman‐Sundberg · 2005 · Journal of Biological Chemistry
  45. Expression and activity of taxane-metobolizing enzymes in ovarian tumors
    Julie A. DeLoia, William C. Zamboni, Jacqueline M. Jones, Sandra Strychor, Joseph Leo Kelley, Holly H. Gallion · 2007 · Gynecologic Oncology
  46. Influence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: implication of a CYP3A4 activity profile.
    Joana Assis, Deolinda Pereira, Mónica Patrícia Gomes, Dânia Sofia Marques, Inês Marques, Augusto Nogueira, Raquel Catarino, Rui Medeiros · 2013 · Europe PMC (PubMed Central)
  47. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans
    Minoli A. Perera, Ranjit Kumar Thirumaran, Nancy Jean Cox, Stephen B. Hanauer, Soma Das, Cynthia Brimer, Vishal Lamba, Erin G. Schuetz, Mark J. Ratain, Anna Di Rienzo · 2008 · The Pharmacogenomics Journal
  48. Cytochrome P450 3A Enzymes Are Key Contributors for Hepatic Metabolism of Bufotalin, a Natural Constitute in Chinese Medicine Chansu
    Ziru Dai, Jing Ning, Guibo Sun, Ping Wang, Feng Zhang, Hongying Ma, Li‐Wei Zou, Jie Hou, Jingjing Wu, Guang‐Bo Ge et al. · 2019 · Frontiers in Pharmacology
  49. Transcriptional regulation of CYP3A4 by nuclear receptors in human hepatocytes under hypoxia
    Xuechun Yuan, Hui Lu, Anpeng Zhao, Yidan Ding, Qiong Min, Rong Wang · 2020 · Drug Metabolism Reviews
  50. Variability in Expression of CYP3A5 in Human Fetal Liver
    Carrie A. Vyhlidal, Robin E. Pearce, Roger Gaedigk, Justina C. Calamia, Diana L. Shuster, Kenneth E. Thummel, James Steven Leeder · 2015 · Drug Metabolism and Disposition
  51. Mechanisms of Reduced Maternal and Fetal Lopinavir Exposure in a Rat Model of Gestational Diabetes
    Gregory J. Anger, Micheline Piquette‐Miller · 2011 · Drug Metabolism and Disposition
  52. Limited contribution of CYP3A5 to the hepatic 6?-hydroxylation of testosterone
    Landry K. Kamdem, Ingolf Meineke, Ina Koch, Ulrich M. Zanger, J rgen Brockm ller, Leszek Wojnowski · 2004 · Naunyn-Schmiedeberg s Archives of Pharmacology
  53. Hormonal Regulation of Hepatic Drug Biotransformation and Transport Systems
    María L. Ruiz, Aldo Domingo Mottino, Viviana Alicia Catania, Mary E. Vore · 2013 · Comprehensive physiology
  54. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: A single- and multiple-dose, open-label pharmacokinetic study in Chinese patients
    Li Zhou, Fan‐Yi Meng, Ophelia Q. P. Yin, Jianxiang Wang, Ying Wang, Yongqiang Wei, Pei Hu, Zhixiang Shen · 2009 · Clinical Therapeutics
  55. CYP3APharmacogenetic Association with Tacrolimus Pharmacokinetics Differs Based on Route of Drug Administration
    Amy L. Pasternak, Lu Zhang, Daniel L. Hertz · 2018 · Pharmacogenomics
  56. Interacciones farmacológicas de los fármacos antihipertensivos
    Francisco J. Morales‐Olivas, Luís Estañ · 2005 · Medicina Clínica
  57. A guide to developing population files for physiologically‐based pharmacokinetic modeling in the Simcyp Simulator
    Liam Curry, Sarah Alrubia, Frédéric Y. Bois, Ruth Clayton, Eman El‐Khateeb, Trevor N. Johnson, Muhammad Faisal, Sibylle Neuhoff, Kris Wragg, Amin Rostami‐Hodjegan · 2024 · CPT Pharmacometrics & Systems Pharmacology
  58. Integrating physiologically based kinetic (PBK) and Monte Carlo modelling to predict inter-individual and inter-ethnic variation in bioactivation and liver toxicity of lasiocarpine
    Jia Ning, Ivonne M.C.M. Rietjens, Marije Strikwold · 2019 · Archives of Toxicology
  59. Pleiotropy and Promiscuity in Pharmacogenomics for the Treatment of Alzheimer's Disease and Related risk factors
    Ramón Cacabelos · 2018 · Future Neurology
  60. Diets Containing Soy Protein Isolate Increase Hepatic CYP3A Expression and Inducibility in Weanling Male Rats Exposed during Early Development
    Martin J. J. Ronis, Ying Chen, Chan-He Jo, Pippa Margaret Simpson, Thomas M. Badger · 2004 · Journal of Nutrition
  61. Study of urinary 6β-hydroxycortisol/cortisol ratio in spot urine sample as a biomarker of 3A4 enzyme activity in healthy and epileptic subjects of Egyptian population
    Ehab S. EL Desoky, Hanan O. Mohamed, Wafaa M. A. Farghaly, Sherifa Ahmed Hamed, Mohsen A. Hedaya, Jean-Pascal Siest · 2005 · Pharmacological Research
  62. Transcription Factor Binding to a Putative Double E-Box Motif Represses CYP3A4 Expression in Human Lung Cells
    Jason S. Biggs, Jie Wan, N. Shane Cutler, Jukka Hakkola, Päivi Uusimäki, Hannu Raunio, Garold S. Yost · 2007 · Molecular Pharmacology
  63. Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer
    Emanuel Buck, Martin Ronald Sprick, Matthias M. Gaida, Carsten Grüllich, Tim Frederik Weber, Esther Herpel, Thomas M. Bruckner, Ronald Koschny · 2019 · Oncology Letters
  64. Disparity in Holoprotein/Apoprotein Ratios of Different Standards Used for Immunoquantification of Hepatic Cytochrome P450 Enzymes
    H. F. Perrett, Zoe E. Barter, B. C. Jones, Hiroshi Yamazaki, GT Tucker, Amin Rostami‐Hodjegan · 2007 · Drug Metabolism and Disposition
  65. CYP3A5 promotes glioblastoma stemness and chemoresistance through fine-tuning NAD+/NADH ratio
    Wentao Hu, Xiaoteng Cui, Hongyu Liu, Ze Li, Xu Chen, Qixue Wang, G J Zhang, Er Wen, Jinxin Lan, Junyi Chen et al. · 2025 · Journal of Experimental & Clinical Cancer Research
  66. A New CYP3A5 Variant, CYP3A5*11, Is Shown to Be Defective in Nifedipine Metabolism in a Recombinant cDNA Expression System
    Su‐Jun Lee, Ilse P. van der Heiden, Joyce A. Goldstein, Ron H. N. van Schaik · 2006 · Drug Metabolism and Disposition
  67. DNA methylation determines the regulation of pregnane X receptor on CYP3A4 expression
    Xiaofei Wang, Luman Wei, Jingke Yang, Yiting Wang, Shitong Chen, Kun Yang, Xiangguang Meng, Lirong Zhang · 2020 · Clinical and Experimental Pharmacology and Physiology
  68. Inter-individual variation in chlorpyrifos toxicokinetics characterized by physiologically based kinetic (PBK) and Monte Carlo simulation comparing human liver microsome and Supersome™ cytochromes P450 (CYP)-specific kinetic data as model input
    Shensheng Zhao, Sebastiaan Wesseling, Ivonne M.C.M. Rietjens, Marije Strikwold · 2022 · Archives of Toxicology
  69. Long-term virus-induced alterations of CYP3A-mediated drug metabolism: a look at the virology, immunology and molecular biology of a multi-faceted problem
    Maria A. Croyle · 2009 · Expert Opinion on Drug Metabolism & Toxicology
  70. Reduced Methylprednisolone Clearance Causing Prolonged Pharmacodynamics in a Healthy Subject Was Not Associated WithCYP3A5*3Allele or a Change in Diet Composition
    Su‐Jun Lee, William J. Jusko, Christine G. Salaita, Karim A. Calis, Michael W. Jann, Vicky E. Spratlin, Joyce A. Goldstein, Yuen Yi Hon · 2006 · The Journal of Clinical Pharmacology
  71. In vitroassessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P450enzyme identification, inhibition, and induction studies
    Yan Li, Diansong Zhou, Stephen Ferguson, Peter N. Dorff, Thomas R. Simpson, Scott W. Grimm · 2010 · Xenobiotica
  72. Single nucleotide polymorphism characterization by mRNA expression imbalance assessment
    Leszek Wojnowski, J rgen Brockm ller · 2004 · Pharmacogenetics
  73. In vitro phase I metabolism of gamabufotalin and arenobufagin: Reveal the effect of substituent group on metabolic stability
    Yujie Feng, Chao Wang, Xiangge Tian, Xiaokui Huo, Lei Feng, Cheng‐Peng Sun, Guang‐Bo Ge, Ling Yang, Jing Ning, Xiaochi Ma · 2017 · Fitoterapia
  74. Principles of Pharmacogenomics
    Y. W. Francis Lam · 2019 · Elsevier eBooks
  75. CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients
    Ruben A.G. van Eerden, Nikki S. IJzerman, Milan van Meekeren, Esther Oomen‐de Hoop, Niels A.D. Guchelaar, Andrea M. W. Visser, Maja Matić, Ron H. N. van Schaik, Peter de Bruijn, Dirk-Jan A. R. Moes et al. · 2023 · Clinical Pharmacokinetics
  76. Regulation of CYP3A genes by glucocorticoids in human lung cells
    Jessica K. Roberts, Chad D. Moore, Erin Gregory Romero, Robert M. Ward, Garold S. Yost, Christopher A. Reilly · 2013 · F1000Research
  77. The influence of a standardized soybean extract (Glycine max) on the expression level of cytochrome P450 genes in vivo.
    Przemysław Michał Mrozikiewicz, Anna Bogacz, Bogusław Czerny, Monika Karasiewicz, Radosław Kujawski, Przemysław Łukasz Mikołajczak, Agnieszka Seremak‐Mrozikiewicz, Edmund Grześkowiak, Teresa Bobkiewicz-Kozłowska · 2010 · PubMed
  78. Principles of Pharmacogenomics
    Y. W. Francis Lam, Larisa H. Cavallari · 2013 · Elsevier eBooks
  79. Cloning, Expression, and Characterization of CYP3A43 in Cynomolgus Macaque (Macaca fascicularis)
    Yasuhiro Uno, Kiyomi Matsuno, Chika Nakamura, Masahiro Utoh, Hiroshi Yamazaki · 2009 · Drug Metabolism Letters
  80. The limited impact of CYP3A5 genotype for the pharmacokinetics of CYP3A substrates
    Oliver Burk, Matthias Georg Schwab · 2007 · European Journal of Clinical Pharmacology
  81. Sex differences in hepatic enzymes and transporters involved in pharmacokinetics
    Mehak Behal, Zachary McCalla, Xinwen Wang · 2025 · Liver Research
  82. Effects of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics of tylerdipine hydrochloride in healthy Chinese subjects
    Sufeng Zhou, Mingxue Tao, Yuanyuan Wang, Lu Wang, Lijun Xie, Juan Chen, Yuqing Zhao, Yun Liu, Hongwen Zhang, Ning Ou et al. · 2018 · Xenobiotica
  83. Pharmacogenomics of Tamoxifen and Irinotecan Therapies
    Alicia Algeciras-Schimnich, Dennis J. O’Kane, Christine L.H. Snozek · 2008 · Clinics in Laboratory Medicine
  84. CYP3A4*22 and CYP3A5*3 impact efficacy and safety of diazepam in patients with alcohol withdrawal syndrome
    Valentin Yurievich Skryabin, Johan Franck, Volker Martin Lauschke, Михаил Сергеевич Застрожин, Шипицын Валерий Валериевич, Evgeny Alekseevich Bryun, Dmitry Alekseevich Sychev · 2022 · Nordic Journal of Psychiatry
  85. CYP3A5*3, CYP3A4*1B and MDR1 C3435T Genotype Distributions in Ecuadorians
    B. Sinués, Jorge Vicente-Romero, Ana Fanlo, E. Mayayo Sinués, Fabricio González‐Andrade, Dora Sánchez-Q, Begoña Martínez‐Jarreta · 2008 · Disease Markers
  86. Pharmacogenetics of Carbamazepine: A Systematic Review on CYP3A4 and CYP3A5 Polymorphisms
    Rachda Riffi, Wefa Boughrara, Amina Chentouf, Wassila Ilias, Narimene Malika Taieb Brahim, Amel Alioua Berrebbah, Fatma Belhoucine · 2024 · CNS & Neurological Disorders - Drug Targets
  87. Ancestry-Adjusted Vitamin D Metabolite Concentrations in Association With Cytochrome P450 3A Polymorphisms
    Robin Taylor Wilson, Loren D. Masters, Jill S. Barnholtz‐Sloan, Anna C. Salzberg, Terryl J. Hartman · 2017 · American Journal of Epidemiology
  88. Pharmacogene Sequencing of a Gabonese Population with Severe Plasmodium falciparum Malaria Reveals Multiple Novel Variants with Putative Relevance for Antimalarial Treatment
    Leyre Pernaute-Lau, Ayôla Akim Adégnika, Yitian Zhou, Jeannot Frejus Zinsou, José Pedro Gil, Sanjeev Krishna, Peter G. Kremsner, Volker Martin Lauschke, Thirumalaisamy Palanichamy Velavan · 2021 · Antimicrobial Agents and Chemotherapy
  89. Prediction of human hepatic clearance with HepaSH monolayers for low-turnover compounds
    Shotaro Uehara, Yuichiro Higuchi, Nao Yoneda, Hiroshi Yamazaki, Hiroshi Suemizu · 2025 · Drug Metabolism and Disposition
  90. Differences of Atomic-Level Interactions between Midazolam and Two CYP Isoforms 3A4 and 3A5
    Shuhui Liu, Qing‐Chuan Zheng, Fu‐Quan Bai · 2023 · Molecules
  91. CYP3A gene variability and cancer cells response to the treatment
    Martina Šemeláková, Lenka Maliničová, Mária Macejová, Peter Pristaš · 2021 · General Physiology and Biophysics
  92. Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report
    Michael W. van Kalleveen, Maudy Walraven, Mathijs P. Hendriks · 2018 · Investigational New Drugs
  93. MarmosetCYP3A21, a model for humanCYP3A4: Protein expression and functional characterization of the promoter
    Sigrid Koehler, Nicolas von Ahsen, Christina Schlumbohm, Abdul Rahman Asif, Ute Gödtel‐Armbrust, Michael Oellerich, Leszek Wojnowski, Victor W. Armstrong · 2006 · Xenobiotica
  94. Future of the Pharmacogenomics of Calcineurin Inhibitors in Renal Transplant Patients
    Huaijun Zhu, Weihong Ge · 2011 · Pharmacogenomics
  95. Cytochrome P450 enzymes— in vitro , in vivo , and in silico studies
    Miia Turpeinen · 2006
  96. Effect of Pregnane X Receptor*1B genetic polymorphisms on postoperative analgesia with fentanyl in Chinese patients undergoing gynecological surgery
    Jingjing Yuan, Xiaojing Ma, Zhisong Li, Yanzi Chang, Wei Zhang, Quancheng Kan, Junkai Hou, Lirong Zhang · 2016 · BMC Medical Genetics
  97. Population Pharmacokinetic/Pharmacogenetic Model of Lopinavir/Ritonavir in HIV-Infected Patients
    Elena López Aspiroz, Dolores Santos Buelga, Salvador Enrique Cabrera Figueroa, María de la Paz Valverde Merino, The Tormes Team, Miguel Cordero Sánchez, Alfonso Domínguez-Gil Hurlé, Ángel Carracedo, María José García Sánchez · 2014 · Personalized Medicine
  98. Genetic Determinants of Response to Statins in Cardiovascular Diseases
    Ghazaleh Ghorbannezhad, Shima Mehrabadi, Negar Golampour-Shamkani, Amir Hossein Barjasteh, Poorya Etesamizadeh, Mohammad Tayyebi, Majid Khazaei, Seyed Mahdi Hassanian, Gordon A. Ferns, Amir Avan · 2024 · Current Cardiology Reviews
  99. Regioselective Versatility of Monooxygenase Reactions Catalyzed by CYP2B6 and CYP3A4: Examples with Single Substrates
    Claudio Erratico, Anand K. Deo, Stelvio M. Bandiera · 2015 · Advances in experimental medicine and biology
  100. Interplay of drug metabolizing enzymes with cellular transporters
    Michaela Böhmdorfer, Alexandra Maier‐Salamon, Juliane Riha, Stefan Brenner, Martina Höferl, Walter Rudolf Jäger · 2014 · Wiener Medizinische Wochenschrift